Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Crane Company

Hess

Zions Bancorp

Five companies will report second-quarter 2022 earnings results next week. These are: EQT, MEDP, CR, HES and ZION.

5 Stocks to Buy Ahead of Q2 Earnings Results Next Week

A Relative Strength Rating upgrade for Medpace shows improving technical performance. Will it continue?

Stocks With Rising Relative Strength: Medpace

Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth

Delek US Hlds

Texas Pacific Land Trust

Invest in stocks like Medpace (MEDP), Texas Pacific Land (TPL) & Delek US Holdings (DK) at the moment for solid earnings growth.

3 Top Stocks to Bet on for Superb Earnings Growth

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2022 financial results after the market close on Monday, July 25, 2022. The Company will host a conference call the following morning, Tuesday, July 26, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10

Medpace Holdings, Inc. to Report Second Quarter 2022 Financial Results on July 25, 2022

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Medpace (MEDP) is a Solid Choice

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think " Yes "

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2022 Earnings Conference Call April 26, 2022 9:00 AM ET Company Participants Lauren Morris – Director-Investor Relations August Troendle – Chief Executive Officer Jesse Geiger – President Kevin Brady – Chief Financial Officer Conference Call Participants Dave Windley – Jefferies Eric Coldwell – Baird Christine Rains – William Blair Paul Knight – KeyBanc Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.

Medpace Holdings' (MEDP) CEO August Troendle on Q1 2022 Results - Earnings Call Transcript

Medpace Holdings Inc's (NASDAQ: MEDP) Q1 revenue increased 27.3% Y/Y to $330.9 million, beating the consensus of $327.09 million. On a constant currency organic basis, revenue increased 28.1%.

Medpace Posts Better Than Expected Q1 Earnings, Lifts FYY22 Profit Outlook

Medpace (MEDP) delivered earnings and revenue surprises of 34.13% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q1 Earnings and Revenues Surpass Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial Results Revenue for the three months ended March 31, 2022 increased 27.3% to $330.9 million, compared to $260.0 million for the comparable prior-year period. On a constant currency organic basis, revenue for the first quarter of 2022 increased 28.1% compared to the first quarter of 2021. Backlog as of March 31,

Medpace Holdings, Inc. Reports First Quarter 2022 Results

Medpace Holdings is a healthy business trading at a discount to its intrinsic value. Price target $193-200.

Medpace Holdings: Recent Price Dislocation Buying Opportunity

CINCINNATI--(BUSINESS WIRE)--Medpace (MEDP), a global clinical research organization (CRO), has partnered with Matthew 25: Ministries, a humanitarian and disaster relief organization, to fund aid shipments to Ukraine and surrounding areas. The contribution will facilitate shipping and distribution of critically needed aid with an estimated value above $2.5 million. It will help hundreds of thousands of people in need in Ukraine and the surrounding areas. "Medpace has offices in both Ukraine and

Medpace Donation to Matthew 25: Ministries Funds Delivery of Relief Supplies to Ukraine

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2022 financial results after the market close on Monday, April 25, 2022. The Company will host a conference call the following morning, Tuesday, April 26, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 3191816. To access the conference call via w

Medpace Holdings, Inc. to Report First Quarter 2022 Financial Results on April 25, 2022

What do they know, how? By a community of over 100,000 world-wide information-gatherers reporting back to Market-Maker HQ trading desks.

Medpace Holdings: Best Medical Diagnostic Stock For Near-Term Price Gain Say Market Makers

The heavy selling pressure might have exhausted for Medpace (MEDP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Medpace (MEDP)

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2021 Results - Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 5.60% and 0.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q4 Earnings Beat Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Full Year 2021 Financial Results Revenue for the three months ended December 31, 2021 increased 18.8% to $308.6 million, compared to $259.7 million for the comparable prior-year period. Revenue for the year ended December 31, 2021 increased 23.4% to $1,142.4 million, compared to $925.9 million for the ye

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Results

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2021 financial results after the market close on Monday, February 14, 2022. The Company will host a conference call the following morning, Tuesday, February 15, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 9164466. To access th

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 14, 2022

23andMe

Mesa Laboratories

These smaller healthcare companies all have 10x potential for investors.

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

Medpace Holdings (MEDP) has been struggling lately, but the selling pressure may be coming to an end soon.

Medpace Holdings (MEDP) Sees Hammer Chart Pattern: Time to Buy?

Medpace supports the biopharmaceutical industry with state of the art research methods to accelerate the approval of drugs.

Medpace: Underestimated Profiter Of The Biopharma Trend

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

News for Medpace Holdings Stock (MEDP)